Saba N.F. et al. [143] investigated the efficacy of combination therapy using pembrolizumab (a PD-1 inhibitor) and cabozantinib (a tyrosine kinase inhibitor) in patients with HNSCC. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.